LY248686, a new inhibitor of serotonin and norepinephrine uptake.
about
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder( R )- N -Methyl-3-(3′-[ 18 F]fluoropropyl)phenoxy)-3-phenylpropanamine ( 18 F-MFP3) as a potential PET imaging agent for norepinephrine transporterDuloxetine in the treatment of stress urinary incontinenceDuloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisonsEffects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomesDuloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation.Duloxetine: a review of its use in the treatment of generalized anxiety disorder.Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.Monoamine reuptake inhibitors in Parkinson's disease.Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.Role of serotonin and noradrenaline in stress urinary incontinence.Effect of age on the pharmacokinetics of duloxetine in women.Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgiaEmerging therapies for neuropathic pain.Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain.Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.Review of duloxetine in the management of diabetic peripheral neuropathic pain.The role of duloxetine in the treatment of anxiety disorders.Motor Cortex Excitability and BDNF Levels in Chronic Musculoskeletal Pain According to Structural PathologyEfficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentaryUse of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.Duloxetine: clinical pharmacokinetics and drug interactions.Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression.Preclinical discovery of duloxetine for the treatment of depression.Duloxetine: a review of its use in the management of major depressive disorder in older adults.Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.In vitro and in vivo evaluation of the effects of duloxetine on P-gp function.Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.Duloxetine in the treatment of stress urinary incontinence.Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression.A selective α2 B adrenoceptor agonist (A-1262543) and duloxetine modulate nociceptive neurones in the medial prefrontal cortex, but not in the spinal cord of neuropathic rats.Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.Duloxetine hydrochloride.Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.
P2860
Q24546277-3146D6D0-E065-4AFD-A23E-0BDAA38A107CQ24610704-AEEE77AF-2C59-480F-A396-8F9C2EAD68DEQ24680252-0B66F0D1-5D14-4418-86D4-890F94514C2EQ33251729-2C9840C8-91AF-4440-8C96-6DBD7E9C02FCQ33552597-232F0507-3AF9-4BF4-A995-2F64C5A01439Q33569581-EB87E510-0CE1-4A2E-9478-47A4299A9E99Q34667325-132D60CD-8874-4610-9506-68A122E77C04Q34983801-ECFC6C4C-4106-4F5F-8FB5-D6BF1D83DB49Q35026535-C9ACCE00-8DE2-4928-8D74-2594048C4C2DQ35080568-4545546F-B02B-48D1-8DD1-717A5E2767A9Q35165280-733B6581-5F02-44C8-A857-EFF2BFD194AEQ35207634-E4AC6F06-E9EF-49AE-92CB-1150DACE887FQ35771624-934AC456-3038-443C-92AD-6BA14EE22168Q35825909-B0FC3C5B-D5F7-4167-B096-6D3F1B0FE24EQ35826128-F236E591-3FD4-4EB6-9E22-08F320846407Q36059500-52AD046F-C2A4-428F-9E0D-D504ACD99A97Q36066028-6708BA86-7A91-4F2C-B38F-C4B028004191Q36150758-ED3193C6-A5A9-43E4-A027-8380EE4533D8Q36220913-C2ED2EEF-0918-47D4-8E9C-59C7181ED69EQ36270312-33E63C17-66FB-4167-AF13-618ED9C0827AQ36596907-89DC2C45-93BD-4BF4-A93C-49D242C7A309Q37062590-F98DB4D9-18AC-4BEE-BCFD-6E6F29B698D1Q37096934-0A857D06-E7C2-4E2B-9FC1-C2DE1958C2E0Q37429717-6AF77BB4-D80F-424A-972B-E7D043C8E9F2Q37449200-35D7DE7E-5B75-45CA-8D5D-E8E8790E974EQ37733559-361BCC99-7B9E-4E49-8372-02436FEEB1EFQ37848815-E1521F9E-6AA5-493D-8461-9FD9FEA8EE05Q37980501-1812BD28-CD00-4F13-8606-85BC0EE4DA38Q38017215-A26090B7-9989-47B3-88E5-604EB5CCD8B6Q38067355-5628934C-E63B-4E58-95ED-371F0DE738A8Q39153130-16909585-E9A0-46ED-B0B4-7D34B79356AAQ39594120-03376EF0-A084-4087-AA5E-0E2F1F751966Q42660985-F133FF1D-A73A-4A79-BF98-203A1FAA1288Q43267071-E4CBEF31-FA17-4E0F-A187-8835BD3F1FB5Q44342182-7D765D9D-C0D8-404C-9DA2-C230A473D12FQ44403143-AC8E9B3C-9E43-4221-89A9-71FD7549E669Q44464099-27A7A177-5CC7-47D3-A9AE-0AF0423F1757Q44756644-CD0795AB-3BE3-4D39-9F7D-3ACFD91EB2CEQ45159589-B94F49E1-B226-4E54-B001-EAE65C92AF08Q46408536-F3F1810E-F043-4DD7-8DC6-31A01C6DB8CA
P2860
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@en
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@nl
type
label
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@en
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@nl
prefLabel
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@en
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@nl
P2093
P356
P1476
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
@en
P2093
D W Robertson
F P Bymaster
J H Krushinski
P2888
P356
10.1038/NPP.1993.4
P407
P577
1993-01-01T00:00:00Z